SFI
GALT icon

Susquehanna Fundamental Investments’s Galectin Therapeutics GALT Stock Holding History

Susquehanna Fundamental Investments’s Portfolio GALT Stock Details GALT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-15,600
Closed -$50K – 1762
2021
Q2 		$50K Buy
+15,600
New +$55.5K ﹤0.01% 1621

Other funds holding GALT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
GWM
Geneos Wealth Management Englewood, Colorado $4.31B AUM 18.36% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
CCB
Cutter & Co Brokerage Ballwin, Missouri $423M AUM 15.02% 1-Year Est. Return
Cambridge Investment Research Advisors
Cambridge Investment Research Advisors Fairfield, Iowa $44.6B AUM 28.94% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
E
Ergoteles New York $68.2M AUM 36.16% 1-Year Est. Return

Susquehanna Fundamental Investments's GALT Position: Q3 2021 in Review

Susquehanna Fundamental Investments sold out of Galectin Therapeutics (GALT) in Q3 2021, closing a stake of 15,600 shares — an estimated $50K sold.

Susquehanna Fundamental Investments first reported a position in GALT in Q2 2021 and held it in 1 quarter. The position peaked at $50K in Q2 2021. 70 funds tracked by Wall St. Rank hold GALT as of Q3 2021.

  • Susquehanna Fundamental Investments reported no remaining Galectin Therapeutics position as of Q3 2021 after selling out during the quarter.
  • Susquehanna Fundamental Investments sold 15,600 Galectin Therapeutics shares in Q3 2021, an estimated $50K.
  • Susquehanna Fundamental Investments first reported a position in Galectin Therapeutics in Q2 2021 and held it in 1 quarter.
  • Susquehanna Fundamental Investments's Galectin Therapeutics position peaked at $50K in Q2 2021.
  • 70 funds tracked by Wall St. Rank held Galectin Therapeutics as of Q3 2021.

Based on Susquehanna Fundamental Investments's 13F filing for Q3 2021, filed 15 Nov 2021.